Xzid 60 XR Tablet contains Gliclazide 60mg, a sulfonylurea class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby lowering blood glucose levels. The extended-release (XR) formulation ensures a gradual and sustained release of the active ingredient, promoting stable glycemic control throughout the day and reducing the risk of hypoglycemia associated with peak plasma concentrations. Xzid 60 XR is indicated for patients inadequately controlled by diet, exercise, and weight reduction alone, either as monotherapy or in combination with other antidiabetic agents. It is essential to monitor blood glucose levels regularly to adjust dosage and prevent adverse effects. Common side effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Patient education on recognizing hypoglycemia symptoms and adherence to prescribed therapy is crucial for optimal outcomes. Xzid 60 XR should be taken orally, preferably with breakfast, to maximize efficacy and minimize gastrointestinal discomfort.